Browsing Tag
CLN-049
1 post
Cullinan Therapeutics showcases early AML response with CLN-049 T-cell engager at ASH 2025
Discover how Cullinan Therapeutics’ CLN-049 showed early AML responses at ASH 2025 and what it could mean for future leukemia treatment and investors.